title: Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
authors.forename: Mar
authors.initials: M
authors.lastname: Masiá
authors.forename: Félix
authors.initials: F
authors.lastname: Gutiérrez
authors.forename: Sergio
authors.initials: S
authors.lastname: Padilla
authors.forename: José M
authors.initials: JM
authors.lastname: Ramos
authors.forename: Javier
authors.initials: J
authors.lastname: Pascual
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D003404:Creatinine; D000225:Adenine; D016049:Didanosine